Tag: Alder Biopharmaceuticals
September 22, 2019
5 Top Weekly NASDAQ Biotech and Pharma Stocks: Lexicon Soars
Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
September 16, 2019
Lundbeck to Buy Alder BioPharma in US$2 Billion Deal
Lundbeck will add Alder BioPharma's potential blockbuster migraine treatment, eptinezumab, to its pipeline ahead of patent expirations. May 6, 2019
Alder BioPharmaceuticals Presents New Data from Clinical Trials
Alder BioPharmaceuticals (NASDAQ:ALDR) has released new data showing consistency of early migraine prevention benefit in four clinical trials with eptinezumab.... October 23, 2018
Alder BioPharmaceuticals Announces Positive Results From Pharmacokinetic Comparability Study for Eptinezumab
Alder Biopharmaceuticals (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced positive... May 9, 2018
Alder BioPharmaceuticals Reports First Quarter 2018 Financial and Operating Results
Alder BioPharmaceuticals (NASDAQ:ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today provided a... April 25, 2018
Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine
Alder BioPharmaceuticals (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new... April 24, 2018